Modelling the cost-effectiveness of a new infant vaccine to prevent tuberculosis disease in children in South Africa.

ABSTRACT:

Background

Tuberculosis remains the leading cause of death in South Africa. A number of potential new TB vaccine candidates have been identified and are currently in clinical trials. One such candidate is MVA85A. This study aimed to estimate the cost-effectiveness of adding the MVA85A vaccine as a booster to the BCG vaccine in children from the perspective of the South African government.

Methods

The cost-effectiveness was assessed by employing Decision Analytic Modelling, through the use of a Markov model. The model compared the existing strategy of BCG vaccination to a new strategy in which infants receive BCG and a booster vaccine, MVA85A, at 4 months of age. The costs and outcomes of the two strategies are estimated through modelling the vaccination of a hypothetical coh

SUBMITTER: Channing L 

PROVIDER: S-EPMC4169661 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature